CARCINOMA, HEPATOCELLULAR
Clinical trials for CARCINOMA, HEPATOCELLULAR explained in plain language.
Never miss a new study
Get alerted when new CARCINOMA, HEPATOCELLULAR trials appear
Sign up with your email to follow new studies for CARCINOMA, HEPATOCELLULAR, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo tested for Tough-to-Treat cancers
Disease control OngoingThis study is testing a new drug called E7386 in combination with other cancer medications for people with advanced solid tumors, including endometrial, liver, and colorectal cancers. The main goals are to find the safest and most effective dose and to see how well the drug combi…
Matched conditions: CARCINOMA, HEPATOCELLULAR
Phase: PHASE1, PHASE2 • Sponsor: Eisai Inc. • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
Major trial aims to extend lives in Tough-to-Treat liver cancer
Disease control OngoingThis study is testing if adding two drugs, lenvatinib and pembrolizumab, to a standard liver cancer procedure (TACE) works better than the procedure alone. It involves about 480 adults with liver cancer that is confined to the liver but cannot be cured by surgery or transplant. T…
Matched conditions: CARCINOMA, HEPATOCELLULAR
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
New drug combo aims to stop liver Cancer's return after transplant
Disease control ENROLLING_BY_INVITATIONThis study is testing if adding a drug called everolimus to standard anti-rejection medications after a liver transplant can better prevent liver cancer from coming back. It will involve about 336 adults with advanced liver cancer who receive a transplant. Researchers will compar…
Matched conditions: CARCINOMA, HEPATOCELLULAR
Phase: PHASE4 • Sponsor: Baylor Research Institute • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC
-
Two-Drug attack aims to stop deadly liver Cancer's return
Disease control OngoingThis large, late-stage trial is testing whether a combination of two immunotherapy drugs (atezolizumab and bevacizumab) can help prevent liver cancer from returning in patients who are at high risk after their initial tumor was surgically removed or destroyed. It compares giving …
Matched conditions: CARCINOMA, HEPATOCELLULAR
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Mar 17, 2026 13:09 UTC